Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime vs Ampicillin/Sulbactam for Post-Cesarean SSI Prevention
NCT06048692Phase 3
Key facts
- Status
- Unknown
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Countries
- 1
- Sponsor
- Beni Suef University
- Modality
- Reversible Covalent Inhibitors
- Drugs
- cefepime
- Conditions
- surgical site infection (SSI)
01
Overview
Phase 3, randomised trial of cefepime in surgical site infection (SSI), sponsored by Beni Suef University. Primary endpoint: Surgical Site Infection at 1 month. Status: unknown.
02
Design
- Study design
- Randomized
03
Who it enrols
Pregnant women over 18 years old undergoing elective cesarean delivery (previous or primary). Excludes those with severe hepatic disease, emergent deliveries, medical disorders (diabetes, anemia, hypertension, preeclampsia), or skin infections near the site.
04
Endpoints
Primary
Surgical Site Infection
Beyond the preview
Go deeper on NCT06048692.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048692.